Skip to main content
Equibles
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc. · Metrics

Track LCTX — free

Use LCTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LCTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.00 +0.02 (+1.52%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Customer concentration — top 2 customers 92% of revenue

2 customers — 92% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”

One customer — 92% of revenue (the year ended December 31, 2024)

“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
View the 10-K filed Mar 5, 2026
Market Cap
$252.91M
Shares
252.91M
Volume · Oct 23 1.15M Avg daily vol (3M) 1.25M

LCTX metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.00
Market cap
$252.91M

Price action

20 metrics
Price change (1W)
+2.2%
Price change (30D)
-2.9%
Price change (3M)
-2.9%
Price change (6M)
-35.5%
Price change (YTD)
-40.1%
Price change (1Y)
-38.7%
Trailing year
Price change (5Y)
-57.4%
52-week high
$1.96
52-week low
$0.90
Change from 52-week high
-49.0%
Change from 52-week low
+10.6%
Annualized volatility
55.8%
Annualized volatility (3M)
53.4%
Beta
1.3
RSI (14D)
52.2
Price vs SMA 50
-2.1%
Price vs SMA 200
-25.6%
Avg volume (3M)
1.25M
Relative volume
0.9
Average dollar volume
$1.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
252.91M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
15.4×
reciprocal yield 6.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
19.3×
reciprocal yield 5.2%
P / book
4.2
reciprocal yield 24.1%
FCF yield
-9.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
18.7×
reciprocal yield 5.4%
EV / revenue historical average (5Y)
18.2×
reciprocal yield 5.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-205.2%
Trailing 12 months
Net margin
-246.6%
Gross profit (TTM)
$9.29M
Operating profit (TTM)
−$26.85M
Net income (TTM)
−$32.26M
Trailing 12 months
Diluted EPS (TTM)
$-0.19
FCF margin
-186.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.05
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.11
EBITDA per diluted share (TTM)
$-0.10
Net income per diluted share (TTM)
$-0.14
Operating cash flow per diluted share (TTM)
$-0.10
Free cash flow per diluted share (TTM)
$-0.10
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.08
Stock compensation per diluted share (TTM)
$0.02
Book value per share
$0.18

Growth

11 metrics
Revenue growth YoY
-61.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$13.08M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.5%
Year over year · more shares
Revenue CAGR (3Y)
-0.3%
Revenue CAGR (5Y)
+51.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-53.0%
Return on assets
-30.4%
Debt / equity
0.0
Current ratio
6.6
EBITDA (TTM)
−$26.11M
Free cash flow (TTM)
−$24.39M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$50.78M
Latest balance sheet
Cash & equivalents
$37.35M
Total assets
$106.22M
Total debt
$48,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$23.82M
Capital expenditures (TTM)
$574,000
R&D (TTM)
$20.52M
SG&A (TTM)
—
Stock compensation (TTM)
$5.07M
R&D / revenue
156.8%
Stock compensation / revenue
38.8%

Ownership (13F)

9 metrics
13F filers
131
13F filer change QoQ
+1
Institutional ownership
46.1%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
23.1%
Private-fund adviser ownership
23.0%
Active holders' share change QoQ
-11.5%
Holder tenure
18.5
Price vs estimated holder cost
-5.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.1%

Short interest

3 metrics
Short interest
11.5%
Latest settlement · 15.8 days to cover
Days to cover
15.8d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 876343 CUSIP 53566P109 13F (30d) 26 filings 26 filers Visit website Investor relations